Logo image
Sign in
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Journal article

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Nicolas Danchin, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, …
08/30/2022
PMCID: PMC9422774
PMID: 35770629

Abstract

Cardiovascular Diseases Apolipoproteins B diagnosis [Acute Coronary Syndrome] Humans Antibodies Cholesterol, LDL Acute Coronary Syndrome/diagnosis Kardiologi Anticholesteremic Agents/adverse effects Antibodies, Monoclonal, Humanized epidemiology acute coronary syndrome LDL Atherosclerosis cholesterol drug therapy [Atherosclerosis] Monoclonal Hydroxymethylglutaryl-CoA Reductase Inhibitors heart disease risk factors Cardiovascular Diseases/diagnosis Atherosclerosis/drug therapy PCSK9 inhibitors Anticholesteremic Agents drug therapy adverse effects [Anticholesteremic Agents] Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Risk Factors Humanized Treatment Outcome prevention & control Physiology (medical) therapeutic use [Hydroxymethylglutaryl-CoA Reductase Inhibitors] PCSK9 inhibitors, acute coronary syndrome, apolipoproteins B, LDL cholesterol Cardiac and Cardiovascular Systems Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use diagnosis [Cardiovascular Diseases] Cardiology and Cardiovascular Medicine PCSK9 inhibitors ; acute coronary syndrome ; apolipoproteins B ; cholesterol, LDL ; heart disease risk factors
Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Published by Ovid, [Erscheinungsort nicht ermittelbar]

Metrics

1 Record Views

Details